ULURU INC. PRESENTS RESULTS OF FIRST RANDOMIZED CLINICAL TRIAL FOR ALTRAZEAL™ AT THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) FALL MEETING IN WASHINGTON D.C.

Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either AltrazealTM or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read More

For Health Care Professionals Only:

To try ALTRAZEAL Transforming Powder Dressing, contact a sales representative for training.

ALTRAZEAL is a revolutionary wound treatment technology that’s changing the landscape of healing. But it won’t stop here. Register to receive:

Press releases
Product Updates
New Clinical Data

Case Studies
Special Offers
Promotions

and the very latest from the world's first transforming powder dressing.

Try ALTRAZEAL
Register

For a list of other organizations which may be of interest to you, click here.

Meetings
Links

Privacy Policy Legal Notice Contact Us